sorafenib has been researched along with hypothemycin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (hypothemycin) | Trials (hypothemycin) | Recent Studies (post-2010) (hypothemycin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 35 | 0 | 18 |
| Protein | Taxonomy | sorafenib (IC50) | hypothemycin (IC50) |
|---|---|---|---|
| Mitogen-activated protein kinase kinase kinase 7 | Homo sapiens (human) | 0.033 | |
| Nuclear receptor subfamily 2 group C member 2 | Homo sapiens (human) | 0.03 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.663 | |
| TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 | Homo sapiens (human) | 0.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bensinger, D; Cremer, A; Engemann, V; Kohl, V; Schmidt, B; Schmitz, K; Stegmaier, K; Stubba, D; Stuckert, J; Waßmer, T | 1 |
1 other study(ies) available for sorafenib and hypothemycin
| Article | Year |
|---|---|
Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line, Tumor; Embryo, Nonmammalian; fms-Like Tyrosine Kinase 3; High-Throughput Screening Assays; Humans; Molecular Docking Simulation; Mutation; Prospective Studies; Protein Kinase Inhibitors; Zebrafish | 2019 |